TBIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TBIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. Translate Bio's tangible book value per share for the quarter that ended in Jun. 2021 was $4.20.
Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.
The historical data trend for Translate Bio's Tangible Book per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Translate Bio Annual Data | |||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | ||||||
Tangible Book per Share | -5.59 | -5.14 | -0.06 | 0.78 | 3.42 |
Translate Bio Quarterly Data | |||||||||||||||||||
Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | |
Tangible Book per Share | Get a 7-Day Free Trial | 2.43 | 3.54 | 3.42 | 3.86 | 4.20 |
For the Biotechnology subindustry, Translate Bio's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Translate Bio's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Translate Bio's Price-to-Tangible-Book falls into.
Translate Bio's Tangible Book Value Per Share for the fiscal year that ended in Dec. 2020 is calculated as
Tangible Book Value per Share | = | (Total Stockholders Equity | - | Preferred Stock | - | Intangible Assets) | / | Shares Outstanding (EOP) |
= | (356.757 | - | 0 | - | 100.486) | / | 75.0296 | |
= | 3.42 |
Translate Bio's Tangible Book Value Per Share for the quarter that ended in Jun. 2021 is calculated as
Tangible Book Value per Share | = | (Total Stockholders Equity | - | Preferred Stock | - | Intangible Assets) | / | Shares Outstanding (EOP) |
= | (412.637 | - | 0 | - | 95.866) | / | 75.3437 | |
= | 4.20 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.
Translate Bio (NAS:TBIO) Tangible Book per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Thank you for viewing the detailed overview of Translate Bio's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Jean Francois Formela | director | C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451 |
Renaud Ronald C Jr | director, officer: Chief Executive Officer, other: President | C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02109 |
Paul D. Burgess | officer: Chief Operating Officer, CLO, other: Secretary | C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421 |
Owen Hughes | director | C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139 |
Shire Human Genetic Therapies, Inc. | 10 percent owner | 300 SHIRE WAY LEXINGTON MA 02421 |
Takeda Pharmaceutical Co Ltd | 10 percent owner | 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668 |
Baupost Group Gp, L.l.c. | 10 percent owner | 10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116 |
Seth A Klarman | 10 percent owner | 10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116 |
Baupost Group Llc/ma | 10 percent owner | 10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116 |
George Demetri | director | BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142 |
Daniella Beckman | director | C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139 |
Robert M Plenge | director | C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421 |
Daniel Lynch | director | |
Robert J. Meyer | director | 2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713 |
Ann Barbier | officer: Chief Medical Officer | 255 STATE STREET, C/O PIERIS PHARMACEUTICALS,INC., BOSTON MA 02109 |
From GuruFocus
By sperokesalga sperokesalga • 06-05-2023
By sperokesalga sperokesalga • 05-15-2023
By GuruFocusNews GuruFocusNews • 07-02-2022
By Marketwired • 08-10-2023
By sperokesalga sperokesalga • 06-06-2023
By Value_Insider Value_Insider • 10-19-2022
By Value_Insider Value_Insider • 11-02-2022
By GuruFocusNews GuruFocusNews • 07-01-2022
By Marketwired • 09-28-2023
By sperokesalga sperokesalga • 05-18-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.